Clinical Trials Logo

Clinical Trial Summary

As a traditional Chinese medicine compound, SaiLuoTong capsule is proven to have beneficial effects on learning and memory ability in animal models of vascular dementia (VaD). The study hypothesis is that SaiLuoTong capsule will be effective in the treatment of patients with VaD and will be well tolerated. The purpose of the study is to determine the efficacy and safety of SaiLuoTong capsule on patients with mild to moderate VaD. The outcome measures include general cognitive function, executive function, daily living skills, and mental behavior changes of symptoms in VaD patients.


Clinical Trial Description

Vascular dementia (VaD) is a clinical syndrome of acquired intellectual and functional impairment that results from cerebrovascular diseases. SaiLuoTong capsule is a traditional Chinese medicine compound; it is composed of ginseng extract (the main composition: ginseng total saponins), ginkgo biloba extract (the main composition: YinXingTong ester) and safflower extract (the main composition: the west safflower total glycosides). The function of SaiLuoTong capsule is Yiqi Huoxue and Huayu Tongluo in Chinese traditional medicine theory. Pharmacodynamics studies showed that SaiLuoTong capsule can significantly improve neurological symptoms caused by focal cerebral ischemia in animals, and learning and memory ability in animal models of VaD. Based on these previous evidences, we conduct this study to assess the efficacy and safety of SaiLuoTong capsule in patients with mild to moderate VaD. This study is a phase 2 clinical trial of SaiLuoTong capsule for treatment of vascular dementia. The initial study is a 26-week, multicentre, randomized, double -blind, placebo-controlled study. Patients who complete the initial 26-week trial will be eligible to continue in a 26-week open-label extension study.

The primary and secondary objectives of this study are as following:

Primary Objectives:

1. To assess the efficacy of SaiLuoTong capsule on cognitive and global functioning in patients with mild-to-moderate VaD;

2. To assess the safety and tolerability of SaiLuoTong capsule in patients with mild-to-moderate VaD.

Secondary Objectives:

1. To assess the efficacy of SaiLuoTong capsule in improving the ability to do activities of daily living, executive function, and neuropsychiatric symptoms in patients with mild-to-moderate VaD;

2. To assess the efficacy of different dosage regimens of SaiLuoTong in patients with mild-to-moderate VaD;

3. To assess the efficacy of SaiLuoTong treatment of different duration in patients with mild-to-moderate VaD;

4. To assess the efficacy of SaiLuoTong capsule on different etiological subtypes of VaD, including large-vessel VaD, small-vessel VaD, and VaD of mixed large-vessel and small-vessel origin;

5. To assess the efficacy of SaiLuoTong capsule in mild VaD patients and moderate VaD patients separately;

6. To assess to effect of apolipoprotein E (ApoE) ε4 allele on trial outcomes.

The study will assess the changes in cognitive function, daily living skills, executive functions, behavioral and psychological symptoms. The primary measures of effectiveness include the change from baseline in the vascular dementia assessment scale cognitive subscale (V-ADAS-cog) and Alzheimer's disease cooperative study-clinical global impression of change (ADCS-CGIC). Secondary measures of effectiveness include the change from baseline in the Alzheimer's disease cooperative study-activities of daily living inventory (ADCS-ADL), mini-mental state examination (MMSE), clinical dementia rating scale (CDR), sum of boxes of CDR(CDR-sb), clock drawing task (CLOX), Chinese version of executive interview 25 (C-EXIT25) and neuropsychiatric inventory (NPI). Safety measures include physical examinations, vital signs, electrocardiography, laboratory tests, and adverse events records. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01978730
Study type Interventional
Source Shineway Pharmaceutical Co.,Ltd
Contact
Status Unknown status
Phase Phase 2
Start date December 2011
Completion date July 2014

See also
  Status Clinical Trial Phase
Completed NCT04567745 - Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers Phase 1
Recruiting NCT04109963 - Trial of Remote Ischemic Pre-conditioning in Vascular Cognitive Impairment Phase 2
Recruiting NCT04335994 - ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing N/A
Not yet recruiting NCT06416371 - Retinal Vessel Leakage in Cerebral Small Vessel Disease
Completed NCT01761227 - Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular Dementia Phase 2
Active, not recruiting NCT01208675 - The Swedish BioFINDER Study
Completed NCT00165763 - Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia Phase 4
Completed NCT00621647 - Seroquel- Agitation Associated With Dementia Phase 3
Recruiting NCT04095962 - Effects of a Multicomponent Exercise Intervention on Physical and Cognitive Function of Older Adults With Dementia N/A
Recruiting NCT03275363 - The University of Hong Kong Neurocognitive Disorder Cohort N/A
Active, not recruiting NCT03804229 - Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia Phase 3
Enrolling by invitation NCT03724136 - Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study N/A
Completed NCT02453932 - Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia Phase 3
Completed NCT00947531 - A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia Phase 4
Not yet recruiting NCT03702543 - Managing Vascular Dementia Risk Factors With SymTrend Phase 1
Enrolling by invitation NCT02147652 - Personalized Music Therapy and Agitation in Dementia N/A
Recruiting NCT04114994 - Longitudinal Cognitive Assessment by BoCA
Recruiting NCT06034509 - Cognitive and Vascular Functioning Following TBI
Recruiting NCT05921266 - Urolithin A Supplementation in Middle-aged Adults With Obesity N/A
Completed NCT01465360 - Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center N/A